{"drugs":["BayRho-D","HyperRHO S\/D","MicRhogam Ultra-Filtered","Rho(D) Immune Globulin","Rhogam","RhoGAM Ultra-Filtered Plus","Rhophylac","WinRho SDF"],"mono":{"0":{"id":"514930-s-0","title":"Generic Names","mono":"Rho(D) Immune Globulin"},"1":{"id":"514930-s-1","title":"Dosing and Indications","sub":[{"id":"514930-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Immune thrombocytopenic purpura, Non-splenectomized, Rho(D) positive patients:<\/b> (Rhophylac(R)) 250 international units\/kg (50 mcg\/kg) IV administered at a rate of 2 mL over 15 to 60 seconds<\/li><li><b>Immune thrombocytopenic purpura, Non-splenectomized, Rho(D) positive patients:<\/b> (WinRho(R) SDF) initial dose, 250 international units\/kg (50 mcg\/kg) IV over 3 to 5 minutes as a single injection or in 2 divided doses given on separate days; if hemoglobin less than 10 g\/dL, reduce initial dose to 125 to 200 international units\/kg (25 to 40 mcg\/kg) IV<\/li><li><b>Immune thrombocytopenic purpura, Non-splenectomized, Rho(D) positive patients:<\/b> (WinRho(R) SDF) maintenance therapy, 125 to 300 international units\/kg (25 to 60 mcg\/kg) IV over 3 to 5 minutes as needed based on clinical response and hemoglobin (Hgb) levels; if patient did not respond to initial dose, give additional 125 to 200 international units\/kg (25 to 40 mcg\/kg) if Hgb is 8 to 10 g\/dL and 250 to 300 international units\/kg (50 to 60 mcg\/kg) if Hgb is greater than 10 g\/dL; if hemoglobin is less than 8 g\/dL, use alternative treatments<\/li><li><b>Immune thrombocytopenic purpura, Secondary to HIV infection in non-splenectomized, Rho(D) positive patients:<\/b> (WinRho(R) SDF) initial dose, 250 international units\/kg (50 mcg\/kg) IV over 3 to 5 minutes as a single injection or in 2 divided doses given on separate days; if hemoglobin less than 10 g\/dL, reduce initial dose to 125 to 200 international units\/kg (25 to 40 mcg\/kg) IV<\/li><li><b>Immune thrombocytopenic purpura, Secondary to HIV infection in non-splenectomized, Rho(D) positive patients:<\/b> (WinRho(R) SDF) maintenance therapy, 125 to 300 international units\/kg (25 to 60 mcg\/kg) IV over 3 to 5 minutes as needed based on clinical response and hemoglobin (Hgb) levels; if patient did not respond to initial dose, give additional 125 to 200 international units\/kg (25 to 40 mcg\/kg) if Hgb is 8 to 10 g\/dL and 250 to 300 international units\/kg (50 to 60 mcg\/kg) if Hgb is greater than 10 g\/dL; if hemoglobin is less than 8 g\/dL, use alternative treatments<\/li><li><b>Rhesus isoimmunization affecting pregnancy, Sensitization of Rho(D) negative females to Rho(D) positive blood; Prophylaxis:<\/b> antepartum prophylaxis (HyperRHO(TM) S\/D Full Dose; RhoGAM(R); Rhophylac(R); WinRho(R) SDF), 300 mcg (1500 international units) IM; give at approximately 28 weeks gestation; if given earlier in pregnancy (before 26 to 28 weeks gestation), repeat dose at 12-week intervals to maintain adequate protection<\/li><li><b>Rhesus isoimmunization affecting pregnancy, Sensitization of Rho(D) negative females to Rho(D) positive blood; Prophylaxis:<\/b> postpartum prophylaxis, if newborn is Rh-positive (HyperRHO(TM); RhoGAM(R); Rhophylac(R)), 300 mcg (1500 international units) IM or IV (Rhophylac(R) only); administer as soon as possible and within 72 hours after delivery;  (WinRho(R) SDF), 120 mcg (600 international units) IM or IV; administer as soon as possible and within 72 hours after delivery<\/li><li><b>Rhesus isoimmunization affecting pregnancy, Sensitization of Rho(D) negative females to Rho(D) positive blood; Prophylaxis:<\/b> abortion, miscarriage, termination of ectopic pregnancy, up to and including 12 weeks gestation (HyperRHO(TM) S\/D Mini-Dose; MICRhoGAM(R)), 50 mcg (250 international units) IM; administer immediately  or within 72 hours<\/li><li><b>Rhesus isoimmunization affecting pregnancy, Sensitization of Rho(D) negative females to Rho(D) positive blood; Prophylaxis:<\/b> abortion, miscarriage, termination of ectopic pregnancy, 13 weeks gestation or greater (HyperRHO(TM) S\/D Full Dose; RhoGAM(R)), Rhophylac(R)) 300 mcg (1500 international units) IM or IV (Rhophylac(R) only); administer within 72 hours<\/li><li><b>Rhesus isoimmunization affecting pregnancy, Sensitization of Rho(D) negative females to Rho(D) positive blood; Prophylaxis:<\/b> abortion or miscarriage after 34 weeks gestation (WinRho(R) SDF), 120 mcg (600 international units) IM or IV; administer immediately or within 72 hours<\/li><li><b>Rhesus isoimmunization affecting pregnancy, Sensitization of Rho(D) negative females to Rho(D) positive blood; Prophylaxis:<\/b> amniocentesis or chorionic villus sampling (HyperRHO(TM) S\/D Full Dose; RhoGAM(R), Rhophylac(R)), 300 mcg IM (1500 international units) or IV (Rhophylac(R) only); administer within 72 hours of procedure; if dose given between 13 and 18 weeks gestation, repeat dose at 26 to 28 weeks<\/li><li><b>Rhesus isoimmunization affecting pregnancy, Sensitization of Rho(D) negative females to Rho(D) positive blood; Prophylaxis:<\/b> amniocentesis or chorionic villus sampling (WinRho(R) SDF), less than 34 weeks gestation, 300 mcg (1500 international units) IM or IV given immediately; repeat dose every 12 weeks during pregnancy; greater than 34 weeks gestation, 120 mcg (600 international units) IM or IV given immediately or within 72 hours<\/li><li><b>Rhesus isoimmunization affecting pregnancy, Sensitization of Rho(D) negative females to Rho(D) positive blood; Prophylaxis:<\/b> abdominal trauma or manipulation (HyperRHO(TM) S\/D Full Dose; RhoGAM(R), Rhophylac(R)), 300 mcg (1500 international units) IM or IV (Rhophylac(R) only); administer within 72 hours after complication\/procedure; if dose given between 13 and 18 weeks gestation, repeat dose at 26 to 28 weeks and within 72 hours of delivery<\/li><li><b>Rhesus isoimmunization affecting pregnancy, Sensitization of Rho(D) negative females to Rho(D) positive blood; Prophylaxis:<\/b> abdominal trauma or manipulation after 34 weeks gestation (WinRho(R) SDF), 120 mcg (600 international units) IM\/IV; administer immediately or within 72 hours<\/li><li><b>Rhesus isoimmunization affecting pregnancy, Sensitization of Rho(D) negative females to Rho(D) positive blood; Prophylaxis:<\/b> excessive fetomaternal hemorrhage (greater than 15 mL; Rhophylac(R) only), 300 mcg (1500 international units) IM or IV plus 20 mcg\/mL fetal RBCs in excess of 15 mL or additional 300 mcg dose if bleeding cannot be quantified; administer within 72 hours of complication<\/li><li><b>Rhesus isoimmunization affecting pregnancy, Sensitization of Rho(D) negative females to Rho(D) positive blood; Prophylaxis:<\/b> threatened abortion with continuation of pregnancy (HyperRHO(TM) S\/D Full Dose; RhoGAM(R); Rhophylac(R); WinRho(R) SDF), 300 mcg (1500 international units) IM or IV (Rhophylac(R) and WinRho(R) SDF only)<\/li><li><b>Rh incompatibility reaction, Suppression of Rh isoimmunization in Rho(D) negative persons transfused with Rho(D) positive RBCs; Prophylaxis - Transfusion:<\/b> (HyperRHO(TM)) dose (number of syringes) = (volume of Rh positive whole blood infused x HCT of donor unit)\/15 mL; if dose calculated results in a fraction, round to next higher whole number of syringes; administer dose IM within 72 hours of exposure<\/li><li><b>Rh incompatibility reaction, Suppression of Rh isoimmunization in Rho(D) negative persons transfused with Rho(D) positive RBCs; Prophylaxis - Transfusion:<\/b> (Rhophylac(R)) 100 international units (20 mcg) IV or IM per 2 mL of transfused blood or 1 mL of erythrocyte concentrate; give within 72 hours of exposure<\/li><li><b>Rh incompatibility reaction, Suppression of Rh isoimmunization in Rho(D) negative persons transfused with Rho(D) positive RBCs; Prophylaxis - Transfusion:<\/b> (MICRhoGAM(R)) exposure to less than 2.5 mL of Rh-positive RBCs, 250 international units (50 mcg) IM; give within 72 hours of exposure<\/li><li><b>Rh incompatibility reaction, Suppression of Rh isoimmunization in Rho(D) negative persons transfused with Rho(D) positive RBCs; Prophylaxis - Transfusion:<\/b> (RhoGAM(R)) exposure to 2.5 mL to 15 mL of Rh-positive RBCs, 1500 international units (300 mcg) IM; give within 72 hours of exposure<\/li><li><b>Rh incompatibility reaction, Suppression of Rh isoimmunization in Rho(D) negative persons transfused with Rho(D) positive RBCs; Prophylaxis - Transfusion:<\/b> (RhoGAM(R)) exposure to greater than 15 mL of Rh-positive RBCs, 20 mcg IM per mL of Rh-positive RBC exposure; multiple doses may be given at the same time or at spaced intervals; give within 72 hours of exposure<\/li><li><b>Rh incompatibility reaction, Suppression of Rh isoimmunization in Rho(D) negative persons transfused with Rho(D) positive RBCs; Prophylaxis - Transfusion:<\/b> (WinRho(R) SDF) exposure to Rho(D) positive Whole Blood, 3000 international units (600 mcg) IV every 8 hours until the total calculated dose (45 international units\/mL transfused whole blood) has been administered; give within 72 hours of exposure<\/li><li><b>Rh incompatibility reaction, Suppression of Rh isoimmunization in Rho(D) negative persons transfused with Rho(D) positive RBCs; Prophylaxis - Transfusion:<\/b> (WinRho(R) SDF) exposure to Rho(D) positive Whole Blood, 6000 international units (1200 mcg) IM every 12 hours until the total calculated dose (60 international units\/mL transfused whole blood) has been administered; give within 72 hours of exposure<\/li><li><b>Rh incompatibility reaction, Suppression of Rh isoimmunization in Rho(D) negative persons transfused with Rho(D) positive RBCs; Prophylaxis - Transfusion:<\/b> (WinRho(R) SDF) exposure to Rho(D) positive RBCs, 3000 international units (600 mcg) IV every 8 hours until the total calculated dose (90 international units\/mL transfused RBCs) has been administered; give within 72 hours of exposure<\/li><li><b>Rh incompatibility reaction, Suppression of Rh isoimmunization in Rho(D) negative persons transfused with Rho(D) positive RBCs; Prophylaxis - Transfusion:<\/b> (WinRho(R) SDF) exposure to Rho(D) positive Red Blood Cells, 6000 international units (1200 mcg) IM every 12 hours until the total calculated dose (120 international units\/mL transfused RBCs) has been administered; give within 72 hours of exposure<\/li><\/ul>"},{"id":"514930-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Immune thrombocytopenic purpura, Non-splenectomized, Rho(D) positive patients:<\/b> (WinRho(R) SDF) initial dose, 250 international units\/kg (50 mcg\/kg) IV over 3 to 5 minutes as a single injection or in 2 divided doses given on separate days; if hemoglobin less than 10 g\/dL, reduce initial dose to 125 to 200 international units\/kg (25 to 40 mcg\/kg) IV<\/li><li><b>Immune thrombocytopenic purpura, Non-splenectomized, Rho(D) positive patients:<\/b> (WinRho(R) SDF) maintenance therapy, 125 to 300 international units\/kg (25 to 60 mcg\/kg) IV over 3 to 5 minutes as needed based on clinical response and hemoglobin (Hgb) levels; if patient did not respond to initial dose, give additional 125 to 200 international units\/kg (25 to 40 mcg\/kg) if Hgb is 8 to 10 g\/dL and 250 to 300 international units\/kg (50 to 60 mcg\/kg) if Hgb is greater than 10 g\/dL; if hemoglobin is less than 8 g\/dL, use alternative treatments<\/li><li><b>Immune thrombocytopenic purpura, Secondary to HIV infection in non-splenectomized, Rho(D) positive patients:<\/b> (WinRho(R) SDF) initial dose, 250 international units\/kg (50 mcg\/kg) IV over 3 to 5 minutes as a single injection or in 2 divided doses given on separate days; if hemoglobin less than 10 g\/dL, reduce initial dose to 125 to 200 international units\/kg (25 to 40 mcg\/kg) IV<\/li><li><b>Immune thrombocytopenic purpura, Secondary to HIV infection in non-splenectomized, Rho(D) positive patients:<\/b> (WinRho(R) SDF) maintenance therapy, 125 to 300 international units\/kg (25 to 60 mcg\/kg) IV over 3 to 5 minutes as needed based on clinical response and hemoglobin (Hgb) levels; if patient did not respond to initial dose, give additional 125 to 200 international units\/kg (25 to 40 mcg\/kg) if Hgb is 8 to 10 g\/dL and 250 to 300 international units\/kg (50 to 60 mcg\/kg) if Hgb is greater than 10 g\/dL; if hemoglobin is less than 8 g\/dL, use alternative treatments<\/li><\/ul>"},{"id":"514930-s-1-6","title":"Dose Adjustments","mono":"<b>(immune thrombocytopenic purpura; WinRho(R) SDF) hemoglobin less than 10 g\/dL:<\/b> reduce initial dose to 125 to 200 international units\/kg (25 to 40 mcg\/kg) IV "},{"id":"514930-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Immune thrombocytopenic purpura, Non-splenectomized, Rho(D) positive patients<\/li><li>Immune thrombocytopenic purpura, Secondary to HIV infection in non-splenectomized, Rho(D) positive patients<\/li><li>Rhesus isoimmunization affecting pregnancy, Sensitization of Rho(D) negative females to Rho(D) positive blood; Prophylaxis<\/li><li>Rh incompatibility reaction, Suppression of Rh isoimmunization in Rho(D) negative persons transfused with Rho(D) positive RBCs; Prophylaxis - Transfusion<\/li><\/ul>"}]},"2":{"id":"514930-s-2","title":"Black Box Warning","mono":"<b>Intravenous (Powder for Solution; Solution)<\/b><br\/>Intravascular hemolysis (IVH) leading to death has been reported in patients treated for immune thrombocytopenic purpura (ITP) with Rho(D) immune globulin. IVH can lead to clinically compromising anemia and multi-system organ failure, including acute respiratory distress syndrome (ARDS), acute renal insufficiency, renal failure, and disseminated intravascular coagulation (DIC). Alert patients and closely monitor for the signs and symptoms of IVH in a health care setting for at least eight hours after administration for ITP. Perform a dipstick urinalysis at  baseline, 2 hours, 4 hours after administration, and prior to the end of the monitoring period. If signs and\/or symptoms of IVH are present or suspected, post-treatment laboratory tests should be performed, including plasma  hemoglobin, haptoglobin, LDH, and plasma bilirubin (direct and indirect).<br\/>"},"3":{"id":"514930-s-3","title":"Contraindications\/Warnings","sub":[{"id":"514930-s-3-9","title":"Contraindications","mono":"<ul><li>anaphylaxis or severe hypersensitivity reaction to human immune globulin, history of<\/li><li>autoimmune hemolytic anemia<\/li><li>hemolysis, pre-existing or at high risk<\/li><li>IgA deficiency with antibodies against IgA; potential for severe hypersensitivity and anaphylactic reactions<\/li><li>infants; do not administer for the suppression of Rh isoimmunization<\/li><\/ul>"},{"id":"514930-s-3-10","title":"Precautions","mono":"<ul><li>intravascular hemolysis, including potentially serious complications (ie, acute respiratory distress syndrome, DIC, acute renal insufficiency, anemia, death), has occurred in patients treated for ITP; age over 65 yr with co-morbid conditions and dose exceeding 300 international units\/kg increase risk; monitor for 8 hr in healthcare setting after therapy<\/li><li>anemia, pre-existing; may increase severity of anemia<\/li><li>fetomaternal hemorrhage late in pregnancy or following delivery; dose adjustment may be required<\/li><li>hemoglobin levels 8 to 10 g\/dL; risk of increasing severity of anemia<\/li><li>hemoglobin levels less than 8 g\/dL; use alternative treatment<\/li><li>human plasma products may contain infectious agents<\/li><li>hypersensitivity, severe, may occur; discontinue use<\/li><li>IgA deficiency; increased risk of hypersensitivity or anaphylaxis in patients with antibodies to IgA; Rhophylac(R) and WinRho(R) SDF contain trace amounts of IgA<\/li><li>newborn infant; should not be given following an Rh-incompatible pregnancy<\/li><li>noncardiogenic pulmonary edema may occur with IV use<\/li><li>renal insufficiency or predisposition to acute renal failure; increased risk for renal dysfunction<\/li><li>Rho(D) negative patients who are Rh immunized should not receive Rho(D) immune globulin<\/li><li>thrombotic events may occur; increased risk with history of atherosclerosis, multiple cardiovascular risk factors, advanced age, coagulation disorders, prolonged immobilization, or known\/suspected hyperviscosity<\/li><li>transfusions for ITP; administer only Rho(D) negative red blood cells and cautiously administer platelets from Rho(D) positive donors<\/li><li>adverse effects potentially related to the use of WinRho(R) SDF should be reported to Baxter Healthcare Corporation at 1-800-423-2090 or the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"514930-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"514930-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk is minimal.<br\/>"}]},"5":{"id":"514930-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site pain (0.5%)<\/li><li><b>Gastrointestinal:<\/b>Nausea (0.7%)<\/li><li><b>Hematologic:<\/b>Extravascular hemolysis (Mild) (21%), Hemoglobin low<\/li><li><b>Neurologic:<\/b>Dizziness (0.5%), Headache (0.5% to 14.3%)<\/li><li><b>Other:<\/b>Malaise (0.5%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Intravascular hemolysis<\/li><li><b>Immunologic:<\/b>Anaphylaxis (rare)<\/li><li><b>Renal:<\/b>Renal failure, acute<\/li><\/ul>"},"6":{"id":"514930-s-6","title":"Drug Name Info","sub":{"0":{"id":"514930-s-6-17","title":"US Trade Names","mono":"<ul><li>BayRho-D<\/li><li>MicRhogam Ultra-Filtered<\/li><li>Rhogam<\/li><li>Rhophylac<\/li><li>WinRho SDF<\/li><li>HyperRHO S\/D<\/li><li>RhoGAM Ultra-Filtered Plus<\/li><\/ul>"},"2":{"id":"514930-s-6-19","title":"Class","mono":"Immune Serum<br\/>"},"3":{"id":"514930-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"514930-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"514930-s-7","title":"Mechanism Of Action","mono":"<ul><li>Systemic: By providing passive Rh o(D) antibody, Rh o(D) immune globulin suppresses the immune response to Rh o(D)-positive blood in nonsensitized Rh o(D)-negative females. This prevents sensitization to the Rh o(D) erythrocyte factor and the subsequent formation of active Rh o(D) antibody. This in turn prevents the occurrence of Rh hemolytic disease (erythroblastosis fetalis) in Rh o(D)-positive neonates, which results from in utero exposure to maternal Rh o(D) antibody. <\/li><li>Rh o(D) immune globulin has been shown to increase platelet counts in non-splenectomized Rh o(D) positive patients with immune thrombocytopenic purpura. The mechanism of action is not fully understood, but it is thought to be due to the formation of anti-Rh o(D) (anti-D)-coated RBC complexes resulting in Fc receptor blockade, thus sparing antibody-coated platelets.<\/li><\/ul>"},"9":{"id":"514930-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/><ul><li>(HyperRHO(TM) S\/D Mini Dose, HyperRHO(TM) S\/D Full Dose, MICRhoGAM(R), and RhoGAM(R)) administer by IM route only; do not administer IV<\/li><li>(WinRho(R) SDF and Rhophylac(R)) may be administered IV or IM; for immune thrombocytopenic purpura, administer by IV route only<\/li><li>Rho(D) immune globulin should not be administered to the neonate<\/li><\/ul><\/li><li><b>Intramuscular<\/b><br\/><ul><li>(Rhophylac(R), HyperRHO(R), RhoGAM(R), MICRhoGAM(R)) available as a ready-to-use, pre-filled syringe and does not require further reconstitution; allow to come to room temperature before administration<\/li><li>(WinRho(R) SDF) available as ready-to-use, single-dose vials and does not require further reconstitution; allow to come to room temperature before administration<\/li><li>inject IM dose into the deltoid muscle of the upper arm or the anterolateral aspects of the upper thigh; gluteal region is not recommended due to the risk of sciatic nerve injury; if the gluteal region is used, use only the upper, outer quadrant<\/li><\/ul><\/li><li><b>Intravenous<\/b><br\/><ul><li>(Rhophylac(R)) available as a ready-to-use, pre-filled syringe and does not require further reconstitution; allow to come to room temperature before administration<\/li><li>(WinRho(R) SDF) available as ready-to-use, single-dose vials and does not require further reconstitution; allow to come to room temperature before administration; if dilution is preferred prior to administration, use NS; do not use D5W for dilution<\/li><li>(Rhophylac(R)) inject at a rate of 2 mL over 15 to 60 seconds<\/li><li>(WinRho(R) SDF) infuse over 3 to 5 minutes for treatment of ITP; inject at a rate of 2 mL over 5 to 15 seconds for suppression of Rh isoimmunization<\/li><\/ul><\/li><\/ul>"},"10":{"id":"514930-s-10","title":"Monitoring","mono":"<ul><li>immune thrombocytopenic purpura: increased platelet count is indicative of efficacy<\/li><li>suppression of Rh isoimmunization; Rho(D) positive red cell clearance is indicative of efficacy<\/li><li>immune thrombocytopenic purpura: renal function (BUN, serum creatinine, and urine output); baseline and periodically following administration; particularly in patients at risk for developing acute renal failure<\/li><li>immune thrombocytopenic purpura: dipstick urinalysis at baseline, 2 hours, and 4 hours after administration as well as at the end of the recommended 8 hour monitoring period in a healthcare setting<\/li><li>immune thrombocytopenic purpura: signs and symptoms of intravascular hemolysis for at least 8 hrs following administration including back pain, shaking chills, fever, discolored urine or hematuria<\/li><li>immune thrombocytopenic purpura: signs and symptoms of transfusion-related acute lung injury including respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, fever; typically occurs within 1 to 6 hrs following infusion<\/li><\/ul>"},"11":{"id":"514930-s-11","title":"How Supplied","mono":"<ul><li><b>MICRhoGAM Ultra-Filtered Plus<\/b><br\/>Intramuscular Solution: 50 MCG<br\/><\/li><li><b>RhoGAM Ultra-Filtered Plus<\/b><br\/>Intramuscular Solution: 300 MCG<br\/><\/li><li><b>Rhophylac<\/b><br\/>Injection Solution: 750 IU\/ML<br\/><\/li><li><b>WinRho SDF<\/b><br\/>Intravenous Solution: 1500 IU, 2500 IU, 5000 IU, 15000 IU<br\/><\/li><\/ul>"},"13":{"id":"514930-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to avoid vaccines during therapy.<\/li><li>This drug may cause headache.<\/li><li>Patients with immune thrombocytopenic purpura should immediately report signs\/symptoms of acute renal failure or intravascular hemolysis (fever, shivering, back pain, discolored or dark urine, swelling, shortness of breath). Intravascular hemolysis is most likely to occur within 4 h of receiving drug.<\/li><li>Tell pregnant patients to call healthcare professional if a treatment is missed, as drug must be given on a fixed schedule.<\/li><\/ul>"}}}